Are you sure you want to leave?
19 August 2020
Professor David Goldsmith* explores this question in a presentation given at Nephro Update Europe (NUE) 2019. A link to the full presentation is provided at the end of this article.
There are many questions concerning the optimal management of secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (ND-CKD) patients. In this 25-minute presentation, entitled ‘Current concepts in the management of SHPT in ND-CKD patients’, Professor Goldsmith summarises the latest developments and highlights the questions for which we still don’t have answers.
Professor Goldsmith begins his presentation by exploring the complexities of chronic kidney disease–mineral and bone disorder (CKD–MBD), the syndrome that encompasses SHPT.1 He explains that, as kidney function declines, several blood parameters lose homeostasis,1,2 and no one knows exactly how they affect each other.
After exploring the association between SHPT, cardiovascular disease, bone disease and mortality,3 Professor Goldsmith lists four questions regarding the management of SHPT that he thinks haven’t been fully answered despite being out in the open since the late 1980s. The questions are:
While discussing these questions, Professor Goldsmith provides his reasoning as to why normalising PTH is rarely a good idea and why relatively high levels of 25D may be needed to control PTH in ND-CKD patients.4
“Should we D or should we not D?” – that is, should vitamin D formulations be used to control PTH levels in CKD patients?
After going over the complexities of vitamin D metabolism and the prevalence of vitamin D deficiency in different populations, Professor Goldsmith looks at the guidelines on the treatment of SHPT in both dialysis and non-dialysis patients as provided by Kidney Disease: Improving Global Outcomes (KDIGO). He explains why he agrees with KDIGO that active vitamin D (AVD) and AVD analogues should not be routinely used in patients with stage 3 or 4 CKD, the reason being that they significantly increase the risk of hypercalcaemia.5 He then highlights the limitations of nutritional vitamin D in the treatment of SHPT in the same patient population, pointing out that, although NVD can increase 25D, it fails to consistently and reliably reduce PTH.6
Thus, targeting SHPT early is challenging for two reasons:
Professor Goldsmith concludes with a look at the pros and cons of using different formulations of 25D, with emphasis on promising
results yielded by a new formulation.8
You can watch the full presentation by Professor Goldsmith on the Streamed-up website.
Footnotes and references
*Emeritus consultant nephrologist at Guy’s and St Thomas’ NHS Foundation Trust; London, UK.
Moe S et al. Kidney Int. 2006;69:1945–53.
Kuro-o M et al. Bone. 2017;100:4–18.
Geng G et al. Osteoporos Int. 2019;30:2019–25.
Ennis JL et al. J Nephrol. 2016;29:63–70.
Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. Kidney Int Suppl. 2017;7:1–59.
Gunnarsson J et al. Poster presented at: 57<sup>th</sup> ERA–EDTA Congress; 2020 June 6–9; virtual.
Cunningham J et al. Clin J Am Soc Nephrol. 2011;6:913–21.
Sprague SM et al. Am J Nephrol. 2016;44:316–25.
You are viewing a website from Vifor Pharma. This material is only intended for healthcare professionals (“HCPs”) from Europe. If you are not the intended audience, please leave this website. By checking the box, you acknowledge that you are a HCP from Europe. Approval conditions for products may vary from country to country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.